Trump Administration
Refine Search
Pharmaceutical
The UK government has sealed a deal to give the USA zero tariffs on pharmaceutical products imported into the country, in return for the National Health Service (NHS) spending more on medicines. 1 December 2025
Pharmaceutical
Escalating US tariff and pricing reforms are pushing pharmaceutical companies to localize manufacturing and rethink their investment priorities, fueling a surge in outsourcing-led strategies and targeted acquisitions. 12 November 2025
Pharmaceutical
George Tidmarsh has resigned as director of the US Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) after being placed on administrative leave late last week. 4 November 2025
Pharmaceutical
Henrik Vestergaard, acting chief executive of Lif, the Danish Pharmaceutical Industry Association, has taken aim at the USA’s most-favored-nation (MFN) drug pricing policy that would tie US prices of prescription drugs to the lowest prices paid in other developed countries. 27 October 2025
Pharmaceutical
US President Donald Trump has said the USA aims to apply favored-nation pricing to popular weight-loss medicines, pointing to a possible drop from $1,300 to about $150 per month. Markets reacted Friday, with Novo Nordisk falling more than 6% and Eli Lilly down over 3%. 20 October 2025
Pharmaceutical
German pharma group Merck KGaA has become the third company to strike a cost-cutting agreement with the Trump administration, joining Pfizer and AstraZeneca in pledging steep price reductions in exchange for relief from planned US tariffs on drug imports. 17 October 2025
Pharmaceutical
UK pharma major AstraZeneca on Friday announced an agreement with US President Donald Trump’s administration to lower the cost of prescription medicines for American patients while preserving America’s cutting-edge biopharmaceutical innovation. 11 October 2025
Pharmaceutical
Danish pharma major Novo Nordisk is considering its options after a US federal appeals court threw out its legal challenge to the Inflation Reduction Act (IRA) drug price negotiation program. 9 October 2025
Pharmaceutical
US lobby group Pharmaceutical Research and Manufacturers of America (PhRMA) revealed that member companies, thanks to President Trump’s new tax law and regulatory streamlining, are investing $500 billion in new USA-based manufacturing and infrastructure, injecting $1.2 trillion into the US economy and creating over 100,000 new jobs, including at least 25,000 direct biopharmaceutical jobs. 7 October 2025
Biotechnology
US biotech major Amgen is the latest drugmaker to announce direct-to-consumer access of medicines, adding to the first such deal from Pfizer that was followed by similar arrangements by Novartis and Boehringer and AstraZeneca in the last few days. 6 October 2025
Biotechnology
M&A news last week featured Denmark-based Genmab’s plans to expand its portfolio with an up to $8 billion acquisition of Dutch biotech Merus along with its cancer candidate petosemtamab. On the research front, Switzerland’s MoonLake Immunotherapeutics saw its shares plunge 90% on disappointing Phase III trial results for its inflammatory disease candidate sonelokimab, and US biotech giant Amgen released new Phase III data on its cardiovascular drug Repatha. Also of note, US pharma giant Pfizer became the first drugmaker to strike a deal with government to lower medicine prices and join President Donald Trump’s Trump\Rx.gov program. 5 October 2025
Pharmaceutical
The US Food and Drug Administration (FDA) will not be able to deal with new drug applications amid the federal government shutdown. 2 October 2025
Pharmaceutical
The USA’s Pfizer has struck a deal with the Trump administration to lower its US medicine prices and invest an additional $70 billion in onshore manufacturing in exchange for shelter from tariffs. 1 October 2025
Pharmaceutical
The US Department of Health and Human Services (HHS) has warned that more than 32,000 of its staff could be furloughed if Congress fails to avert a federal government shutdown this week, raising the risk of disruption across public health and medical research. 30 September 2025
Pharmaceutical
President Donald Trump has called on US industries to put America first, and the biopharmaceutical sector is answering that call with major actions to demonstrate its commitment to American patients and workers. 30 September 2025
Biotechnology
With US President Donald Trump pushing pharma to put America first and reduce US drug prices, which are much higher than anywhere else in the developed world, domestic and other drugmakers have been attracted to a new scheme to sell their medicines direct to consumers/patients, thus avoiding the substantial margins taken by middlemen. 29 September 2025
Pharmaceutical
French pharma Sanofi has widened its Insulins Valyou Savings Program, announcing that from January 1 all US patients with a valid prescription can buy a 30-day supply of any Sanofi insulin for a flat $35. The scheme was previously restricted to the uninsured. 29 September 2025
Pharmaceutical
"Import duties on medicines are always harmful, especially when they are so exorbitant. They disrupt supply chains and drive up costs, and only hinder access to treatments that patients desperately need," says Carla Vos, chief executive of the Dutch Association of Innovative Medicines (VIG). 27 September 2025
Generics
India’s drugmakers must diversify exports beyond the USA to soften the impact of new tariffs, according to GlobalData. The advisory follows Washington’s confirmation that 100% duties on branded medicines will apply from October 1, 2025, raising concern over future risks to India’s dominant generic sector. 26 September 2025
Pharmaceutical
After months of threats, posturing, rumors and industry concern, US President Donald Trump has finally revealed details of the tariffs that will be applied to branded pharmaceutical products entering the USA. 26 September 2025
Pharmaceutical
The UK government has sealed a deal to give the USA zero tariffs on pharmaceutical products imported into the country, in return for the National Health Service (NHS) spending more on medicines. 1 December 2025
Pharmaceutical
Escalating US tariff and pricing reforms are pushing pharmaceutical companies to localize manufacturing and rethink their investment priorities, fueling a surge in outsourcing-led strategies and targeted acquisitions. 12 November 2025
Pharmaceutical
George Tidmarsh has resigned as director of the US Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) after being placed on administrative leave late last week. 4 November 2025
Pharmaceutical
Henrik Vestergaard, acting chief executive of Lif, the Danish Pharmaceutical Industry Association, has taken aim at the USA’s most-favored-nation (MFN) drug pricing policy that would tie US prices of prescription drugs to the lowest prices paid in other developed countries. 27 October 2025
Pharmaceutical
US President Donald Trump has said the USA aims to apply favored-nation pricing to popular weight-loss medicines, pointing to a possible drop from $1,300 to about $150 per month. Markets reacted Friday, with Novo Nordisk falling more than 6% and Eli Lilly down over 3%. 20 October 2025
Pharmaceutical
German pharma group Merck KGaA has become the third company to strike a cost-cutting agreement with the Trump administration, joining Pfizer and AstraZeneca in pledging steep price reductions in exchange for relief from planned US tariffs on drug imports. 17 October 2025
Pharmaceutical
UK pharma major AstraZeneca on Friday announced an agreement with US President Donald Trump’s administration to lower the cost of prescription medicines for American patients while preserving America’s cutting-edge biopharmaceutical innovation. 11 October 2025
Pharmaceutical
Danish pharma major Novo Nordisk is considering its options after a US federal appeals court threw out its legal challenge to the Inflation Reduction Act (IRA) drug price negotiation program. 9 October 2025
Pharmaceutical
US lobby group Pharmaceutical Research and Manufacturers of America (PhRMA) revealed that member companies, thanks to President Trump’s new tax law and regulatory streamlining, are investing $500 billion in new USA-based manufacturing and infrastructure, injecting $1.2 trillion into the US economy and creating over 100,000 new jobs, including at least 25,000 direct biopharmaceutical jobs. 7 October 2025
Biotechnology
US biotech major Amgen is the latest drugmaker to announce direct-to-consumer access of medicines, adding to the first such deal from Pfizer that was followed by similar arrangements by Novartis and Boehringer and AstraZeneca in the last few days. 6 October 2025
Biotechnology
M&A news last week featured Denmark-based Genmab’s plans to expand its portfolio with an up to $8 billion acquisition of Dutch biotech Merus along with its cancer candidate petosemtamab. On the research front, Switzerland’s MoonLake Immunotherapeutics saw its shares plunge 90% on disappointing Phase III trial results for its inflammatory disease candidate sonelokimab, and US biotech giant Amgen released new Phase III data on its cardiovascular drug Repatha. Also of note, US pharma giant Pfizer became the first drugmaker to strike a deal with government to lower medicine prices and join President Donald Trump’s Trump\Rx.gov program. 5 October 2025
Pharmaceutical
The US Food and Drug Administration (FDA) will not be able to deal with new drug applications amid the federal government shutdown. 2 October 2025
Pharmaceutical
The USA’s Pfizer has struck a deal with the Trump administration to lower its US medicine prices and invest an additional $70 billion in onshore manufacturing in exchange for shelter from tariffs. 1 October 2025
Pharmaceutical
The US Department of Health and Human Services (HHS) has warned that more than 32,000 of its staff could be furloughed if Congress fails to avert a federal government shutdown this week, raising the risk of disruption across public health and medical research. 30 September 2025
Pharmaceutical
President Donald Trump has called on US industries to put America first, and the biopharmaceutical sector is answering that call with major actions to demonstrate its commitment to American patients and workers. 30 September 2025
Biotechnology
With US President Donald Trump pushing pharma to put America first and reduce US drug prices, which are much higher than anywhere else in the developed world, domestic and other drugmakers have been attracted to a new scheme to sell their medicines direct to consumers/patients, thus avoiding the substantial margins taken by middlemen. 29 September 2025
Pharmaceutical
French pharma Sanofi has widened its Insulins Valyou Savings Program, announcing that from January 1 all US patients with a valid prescription can buy a 30-day supply of any Sanofi insulin for a flat $35. The scheme was previously restricted to the uninsured. 29 September 2025
Pharmaceutical
"Import duties on medicines are always harmful, especially when they are so exorbitant. They disrupt supply chains and drive up costs, and only hinder access to treatments that patients desperately need," says Carla Vos, chief executive of the Dutch Association of Innovative Medicines (VIG). 27 September 2025
Generics
India’s drugmakers must diversify exports beyond the USA to soften the impact of new tariffs, according to GlobalData. The advisory follows Washington’s confirmation that 100% duties on branded medicines will apply from October 1, 2025, raising concern over future risks to India’s dominant generic sector. 26 September 2025
Pharmaceutical
After months of threats, posturing, rumors and industry concern, US President Donald Trump has finally revealed details of the tariffs that will be applied to branded pharmaceutical products entering the USA. 26 September 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A TechBio company that specializes in developing personalized vaccines and immunotherapies through its advanced AI-Immunology™ platform. The company bridges artificial intelligence technology, bioinformatics, and drug development to bring novel immunotherapies to patients facing cancer and infectious diseases.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze